Kanghong Pharma Gains NMPA Approval for Innovative Eye Injection KH631
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving clinical trial approvals...
Antengene’s ATG-008 Shows Promising Results in Cervical Cancer and Hepatocellular Carcinoma Studies
Shanghai-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced positive preliminary results from the TORCH-2...
CStone Pharmaceuticals Launches AML Public Welfare Project with China Social Welfare Foundation
The acute myeloid leukemia (AML) public welfare project, initiated by the China Social Welfare Foundation...
Betta Pharmaceuticals’ BPI-D0316 Accepted for NMPA Review for NSCLC Adjuvant Therapy
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced that its clinical trial filing for...
Kelun-Biotech’s SKB264 Receives FDA Approval for Phase II Study
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the US FDA to...
Junovabio Secures Pre-Series A Funding for Tumor Molecular Diagnosis
Junovabio, a Shanghai-based molecular diagnostics specialist, has reportedly raised “tens of millions” of renminbi in...
Lupeng Pharma Raises USD 35 Million in Pre-Series B Financing Round
China-based Lupeng Pharmaceutical Ltd has reportedly raised USD 35 million in Phase 2 of a...
Peru Approves BMS’s Reblozyl and BeiGene’s Brukinsa
Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) has approved Bristol-Myers Squibb’s (BMS; NYSE:...
Silk Round Fund and INA Invest in Indonesian Pharma Companies
The Chinese state-owned Silk Round Fund (SRF) and Indonesia’s sovereign fund INA have reportedly agreed...
LaNova Medicines Gets NMPA Approval for LM-305 Clinical Study
Shanghai-based cancer therapy developer LaNova Medicines Ltd has announced that it has received approval from...
Everest Medicines’ Nefecon NDA Accepted for IgA Nephropathy in China
China-based biotech Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has...
CStone Pharmaceuticals Suspends Suzhou Plant Operations to Cut Costs
CStone Pharmaceuticals (HKG: 2616) has officially responded to recent news reports regarding the suspension of...
Hotgen Receives NMPA Approval for HBV RNA Assay Kit
China-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced that it has received marketing approval...
Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity
China-based Innovent Biologics, Inc. (HKG: 1801) has announced the first patient dosing in the randomized,...
Guangdong Zhongsheng Starts Phase III Trial for COVID-19 Drug RAY1216
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the enrollment of the first...
Yabao Receives FDA Clearance for Generic Nexavar
China-based Yabao Pharmaceutical Group Co., Ltd (SHA: 600351) has announced that it has received Abbreviated...
Hansoh Pharmaceutical Licenses Biotheus’ Bispecific Antibody PM1080 for Greater China
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with fellow...
Sansure Biotech Partners with UBC to Manufacture in Indonesia
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has entered into a local manufacturing...
HutchMed Shifts Focus to Late-Stage Pipeline for Regulatory Approvals
Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) has announced a strategic shift to focus...
Harbour BioMed and WuXi Biologics Announce Strategic Collaboration
Harbour BioMed (HKG: 2142), a global biotechnology company with operations in the United States, the...